CAR-T · Evidence & updates
Sources and verification notes
Primary literature, explicit evidence labels and links back to the original record.
In this chapter
Primary publications, regulatory communications, consensus documents, trial records and original safety reporting are distinguished below. Where full text was unavailable, the access note states that limitation. A source’s inclusion does not make every conclusion equally certain.
Sources
[1] Primary research · 2022-09-15
Mackensen et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine.
Open original source ↗[2] Primary research · 2024-02-21
Müller et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. NEJM.
Open original source ↗[3] Primary research · 2026-01-07
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nature Medicine.
Open original source ↗[4] Primary research · 2026-01-29
Hong et al. BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial. J Hematol Oncol.
Open original source ↗[5] Primary research · 2026-08-27
Albach et al. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial. Nature Medicine.
Publisher abstract and publication metadata reviewed; no claim of full supplementary-data review.
Open original source ↗[6] Primary research · 2026-02-05
Becilli et al. Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases. Nature Medicine.
Publisher/PubMed abstract and metadata; detailed numerical efficacy extraction deliberately limited.
Open original source ↗[7] Primary research · 2025-09-24
Feng et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory SLE: a phase 1 trial. Nature Medicine.
Primary abstract reviewed; two separately manufactured products, not a single dual-target construct.
Open original source ↗[8] Primary research · 2025-08-27
Wang et al. Allogeneic CD19-targeting T cells for treatment-refractory SLE: a phase 1 trial. Nature Medicine.
YTS109 uses a synthetic TCR and antigen receptor (STAR); do not describe all engineered T-cell products as identical conventional CARs.
Open original source ↗[9] Primary research · 2026-01-09
Vu et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine.
Open original source ↗[10] Primary research · 2026-01-09
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. Nature Medicine.
Companion analysis of the MG trial, not an independent efficacy cohort.
Open original source ↗[11] Primary research · 2025-09-17
Wang et al. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus. NEJM.
Primary correspondence/abstract; early human proof of concept, not confirmatory trial evidence.
Open original source ↗[12] Primary research · 2026-09-02
Cheng et al. Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders. NEJM.
Primary correspondence/abstract; neurologic cohort, not a rheumatology efficacy trial.
Open original source ↗[13] Primary research · 2026-05-23
Rius Rigau et al. Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells. Nature Communications.
Mechanistic tissue study; includes CASTLE/named-patient material, not wholly independent treatment cohort.
Open original source ↗[14] Primary research · 2025-01-31
Minopoulou et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in bone marrow in therapy-refractory ANCA-associated vasculitis. Ann Rheum Dis.
Human case report; not a controlled vasculitis trial.
Open original source ↗[15] Primary research · 2024
CAR T-cell therapy in a patient with Sjögren’s syndrome and diffuse large B-cell lymphoma. Primary report, PubMed 38173731.
Concurrent lymphoma materially limits inference about Sjögren’s-specific efficacy.
Open original source ↗[16] Primary research · 2025
PD-1-directed CAR T-cell investigation in Sjögren’s disease. Primary report, PubMed 40026078.
Preclinical therapeutic evidence; not human treatment efficacy.
Open original source ↗[17] Primary research · 2024
Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nature Communications.
Preclinical CAR-Treg work; not clinical proof of tolerogenic therapy in SLE.
Open original source ↗[18] Primary research · 2025-07-11
Tur et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann Rheum Dis.
Small nonrandomized tissue comparison, not a clinical head-to-head efficacy trial.
Open original source ↗[19] Primary research · 2026-09-10
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial. Nature Medicine.
A-319 is a bispecific antibody/T-cell engager, not CAR T-cell therapy.
Open original source ↗[20] Primary research · 2025-04-30
Hagen et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatology.
Open original source ↗[21] Expert consensus · 2023-03-09
Hines et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther.
Read with the published erratum; clinical algorithms must use corrected units.
Open original source ↗[22] Correction · 2025-10-30
Hines et al. Erratum: IEC-HS consensus article. Transplant Cell Ther.
June 2026 issue. Corrects anakinra units in Table 3 from mcg to mg. No dosing table is reproduced here.
Open original source ↗[23] Expert consensus · 2024-07-30
Shahid et al. ASTCT best practice: infection prevention and management after CAR T-cell therapy for hematological malignancies.
Oncology-based recommendations; adapt within autoimmune trial/center protocols, not automatic identical application.
Open original source ↗[24] Expert clinical framework · 2025-11-28
Caricchio et al. A Guide for Initiating and Managing CAR T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases. ACR Open Rheumatology.
Open original source ↗[25] Expert consensus · 2024-02-10
Greco et al. Innovative cellular therapies for autoimmune diseases: EBMT position statement and clinical practice recommendations. eClinicalMedicine.
Historical 2024 recommendations; the 2026 EBMT–ISCT–JACIE consensus is the current update (see [45]).
Open original source ↗[26] Regulatory primary source · Approved list initially checked 2026-09-25; rheumatology indication reassessed 2026-11-13
FDA. Approved Cellular and Gene Therapy Products.
No FDA-approved CAR-T indication for a rheumatic autoimmune disease identified at cutoff; do not generalize this statement to every jurisdiction.
Open original source ↗[27] Regulatory safety communication · 2024-04-18
FDA. Boxed warning for T-cell malignancies after BCMA- or CD19-directed autologous CAR T-cell immunotherapies.
Open original source ↗[28] Regulatory safety communication · 2025-06-26
FDA. Elimination of REMS for autologous CAR T-cell immunotherapies.
Administrative changes do not remove boxed warnings or override investigational protocols.
Open original source ↗[29] Original company-spokesperson reporting · 2026-09-01
FirstWord Pharma. Novartis pauses immunology/neuro CAR-T studies after three patient deaths. Direct company-spokesperson reporting.
Public safety disclosure, not a peer-reviewed denominator-based safety analysis; no verified restart identified in this review.
Open original source ↗[30] Original news reporting · 2026-09-01
Reuters. Novartis pauses autoimmune cell-therapy studies; separate BMS zola-cel pause reported.
This September report predates BMS’s October disclosure of a death in Breakfree-2. The two programs had different events; do not pool them or infer causation from the timing of a death alone.
Open original source ↗[31] Trial-center registry record · 2026
UC Irvine clinical trial record. Descartes-08 in dermatomyositis and antisynthetase syndrome (TRITON), NCT07391605.
Protocol identity/design verified; live enrollment availability not independently confirmed with the site.
Open original source ↗[32] Trial registry · Registry link
ClinicalTrials.gov. CASTLE — NCT06347718.
Identifier verified from primary CASTLE paper. Live registry API could not be retrieved; recruitment status not certified.
Open original source ↗[33] Trial registry · Registry link
ClinicalTrials.gov. COMPARE — NCT06475495.
Identifier verified from primary COMPARE paper. Recruitment status must be checked with the center.
Open original source ↗[34] Trial registry · Registry link
ClinicalTrials.gov. AUTOGRAPH-SLE/LN — NCT06581198.
Do not treat an indexed registry label as clearance to recruit after the 2026 rap-cel safety pause.
Open original source ↗[35] Randomized controlled trial · 2018-01-03
Sullivan et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma (SCOT). NEJM.
AHSCT versus cyclophosphamide, not CAR-T versus AHSCT.
Open original source ↗[36] Conference abstracts · 2026-09-16
PReS 2026 congress proceedings. Pediatric Rheumatology.
Abstract-level updates; individual reports may overlap already published pediatric cohorts.
Open original source ↗[37] Primary research · 2026
Clinical and Cytokine Features of IEC-HS. Blood Cancer Discovery.
CD22 CAR-T in hematologic malignancies; its incidence must not be imported into autoimmune CD19 cohorts.
Open original source ↗[38] Primary research · 2026-03-05
He et al. Dual-targeting BCMA–CD19 CAR-T in SLE: single-cell and immune repertoire analysis. Arthritis & Rheumatology.
Accepted manuscript online March 5; version of record April 2, 2026. Integrated external datasets are not a randomized comparison.
Open original source ↗[39] Primary consensus definition · 2021
van Vollenhoven et al. 2021 DORIS definition of remission in SLE. Lupus Science & Medicine.
Open original source ↗[40] Primary research · 2026-07-22
Zeng et al. Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med.
Primary abstract reviewed; August 14, 2026 issue. Five-patient phase 1 cohort; CAR-NK, not CAR-T.
Open original source ↗[41] Primary research · 2016-06-30
Ellebrecht et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science.
Foundational preclinical DSG3-CAAR work in pemphigus models; not clinical proof in systemic rheumatic disease.
Open original source ↗[42] Primary research · 2026
Hua et al. Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis. Theranostics.
Animal models and human organoid experiments; human organoids are not treated patients.
Open original source ↗[43] Primary research · 2026
Targeting fibroblast activation protein-α to treat renal fibrosis. Primary report, PubMed 41906119.
Preclinical mouse renal-fibrosis models; not a lupus-nephritis or human CKD efficacy trial.
Open original source ↗[44] Original reporting with direct company-spokesperson statements · 2026-09-01
BioSpace. Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events.
A safety disclosure, not an adjudicated trial analysis or a denominator-based estimate.
Open original source ↗[45] Updated international expert consensus · 2026-10-05
Greco et al. CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations. Lancet Rheumatology. 2026;8:e888–e907.
Updates the 2024 practice guidance. Expert-based recommendations, not FDA marketing approval.
Open original source ↗[46] Sponsor safety disclosure · 2026-10-23
Bristol Myers Squibb. Breakfree-2 zola-cel multiple-sclerosis phase 1 disclosure.
One death following septic pneumonia was reported; the causal contribution of zola-cel has not been established. This disclosure must not be confused with the Novartis fatal IEC-HS reports.
Open company disclosure ↗[47] Regulatory submission reported by sponsor · 2026-11-12
Kyverna Therapeutics. Completion of rolling BLA submission for miv-cel in stiff person syndrome.
Submission and request for priority review are not FDA acceptance, priority-review designation or marketing approval. Stiff person syndrome is a neurological indication.
Open company disclosure ↗